$MYOV Just so everyone can be clear and understand what is going on with this crazy buying from Roivant: PART 1 1) Roivant used to own Myovant in its entirety, but sold a (majority) of itself, (Roivant) to Sumitomo for $3B. 2) As of last week, Roivant owned 46.5% of Myovant, the rest held by institutions and retail. 3) Part of the agreement was that upon closing of the $3B acquisition, Sumitomo (Roivant) now, would own no less than a majority, 51% minimum of Myovant... 4) What you are seeing is Roivant clawing back enough shares on the open market and through Takeda subsidiary to gain that 51% minimum majority ownership. 5) What I believe will happen next is there will be 2 more data read outs within q1 and q2 of 2020, followed by NDA submission for Relugolix in q2 of 2020 for Prostate Cancer indication. 6)Sumitomo Dainippon has their cash cow drug patent expiring in 2023, in essence they need this blockbuster, Relugolix, badly.